junlin jiang

Dr. junlin jiang

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
BNBingxuan Niu
Bingxuan Niu
XXXu Xie
Xu Xie
XXXiaoming Xiong
Xiaoming Xiong
JJjunlin jiang
junlin jiang

1 March 2015 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
QYQiong Yuan
Qiong Yuan
CHChang-Ping Hu
Chang-Ping Hu
ZGZhi-Cheng Gong
Zhi-Cheng Gong
YBYong-Ping Bai
Yong-Ping Bai
SLSi-Yu Liu
Si-Yu Liu
JJjunlin jiang
junlin jiang

1 June 2017 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
XZXiao-Zhou Zou
Xiao-Zhou Zou
ZGZhi-Cheng Gong
Zhi-Cheng Gong
TLTing Liu
Ting Liu
FHFang He
Fang He
TZTian-Tian Zhu
Tian-Tian Zhu
CHChang-Ping Hu
Chang-Ping Hu

28 August 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SHShuangyi He
Shuangyi He
LYLi Yan
Li Yan
CYChao Yuan
Chao Yuan
WLWenxuan Li
Wenxuan Li
TWTian Wu
Tian Wu
JJjunlin jiang
junlin jiang

1 August 2013 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
HQHong Qiu
Hong Qiu
JJjunlin jiang
junlin jiang
MLMiao Liu
Miao Liu
XHXin Huang
Xin Huang
SDShi-Jian Ding
Shi-Jian Ding
LWLianchun Wang
Lianchun Wang
Heparan sulfate (HS) is a linear, abundant, highly sulfated polysaccharide that expresses in the vasculature. Recent genetic studies documented that HS critically modulates various endothelial cell functions. However, elucidation of the underlying molecular mechanism has been challenging because of the presence of a large number of HS-binding ligands found in the examined experimental conditions. In this report, we used quantitative phosphoproteomics to examine the global HS-dependent signaling by comparing wild type and HS-deficient endothelial cells that were cultured in a serum-containing medium. A total of 7222 phosphopeptides, corresponding to 1179 proteins, were identified. Functional correlation analysis identified 25 HS-dependent functional networks, and the top five are related to cell morphology, cellular assembly and organization, cellular function and maintenance, cell-to-cell communication, inflammatory response and disorder, cell growth and proliferation, cell movement, and cellular survival and death. This is consistent with cell function studies showing that HS deficiency altered endothelial cell growth and mobility. Mining for the underlying molecular mechanisms further revealed that HS modulates signaling pathways critically related to cell adhesion, migration, and coagulation, including ILK, integrin, actin cytoskeleton organization, tight junction and thrombin signaling. Intriguingly, this analysis unexpectedly determined that the top HS-dependent signaling is the IGF-1 signaling pathway, which has not been known to be modulated by HS. In-depth analysis of growth factor signaling identified 22 HS-dependent growth factor/cytokine/growth hormone signaling pathways, including those both previously known, such as HGF and VEGF, and those unknown, such as IGF-1, erythropoietin, angiopoietin/Tie, IL-17A and growth hormones. Twelve of the identified 22 growth factor/cytokine/growth hormone signaling pathways, including IGF-1 and angiopoietin/Tie signaling, were alternatively confirmed in phospho-receptor tyrosine kinase array analysis. In summary, our SILAC-based quantitative phosphoproteomic analysis confirmed previous findings and also uncovered novel HS-dependent functional networks and signaling, revealing a much broader regulatory role of HS on endothelial signaling.

13 June 2006 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Open access
PDF file
SWShan Wang
Shan Wang
JJjunlin jiang
junlin jiang
CHChang‐Ping Hu
Chang‐Ping Hu
XZXiao‐Jie Zhang
Xiao‐Jie Zhang
DYDong‐Liang Yang
Dong‐Liang Yang
YLYuan‐Jian Li
Yuan‐Jian Li
Background Previous investigations have indicated that the level of asymmetric dimethylarginine (ADMA) is increased in diabetic patients and animals, and rosiglitazone has a protective effect on the endothelium. In the present study, we tested the relationship between protective effects of rosiglitazone and ADMA in streptozotocin (STZ)‐induced diabetic rats and cultured endothelial cells. Methods Blood samples were collected from carotid artery. Vasodilator responses to acetylcholine (ACh) in the isolated aortic rings were measured, and serum concentrations of glucose, lipid, nitrite/nitrate, ADMA and tumour necrosis factor‐α (TNF‐α) were determined. Cultured endothelial cells were treated with ADMA, and the concentrations of intercellular adhesion molecule (ICAM‐1), TNF‐α, and the activity of nuclear factor‐κB (NF‐κB) were determined. Results Vasodilator responses to ACh were decreased markedly and the serum concentrations of TNF‐α, nitrite/nitrate and ADMA were increased significantly in diabetic rats. Rosiglitazone (3, 10 or 30 mg/kg) produced a significant reduction of the inhibition of vasodilator responses to ACh, but had no effect on the serum concentrations of glucose, lipid, nitrite/nitrate and ADMA in diabetic rats. ADMA (30 µM) significantly increased the activity of NF‐κB and elevated the levels of ICAM‐1 and TNF‐α, and pre‐treatment with rosiglitazone (10 or 30 µM) markedly inhibited the increased activity of NF‐κB and reduced the elevated levels of TNF‐α and ICAM‐1 induced by ADMA in cultured endothelial cells. Conclusions Rosiglitazone improves endothelial function in diabetic rats, which is related to the reduction of the inflammatory response induced by ADMA. Copyright © 2006 John Wiley & Sons, Ltd.